Analysis shows gaps in treatment initiation and access between
Caucasians and African Americans following multiple myeloma diagnosis
SUMMIT, N.J.--(BUSINESS WIRE)--
Celgene Corporation (NASDAQ:CELG) today announced the presentation of a
study comparing treatment patterns, healthcare costs and overall
survival between African American and Caucasian Medicare beneficiaries
with newly diagnosed multiple myeloma. The study, which was presented by
Dr. Sikander Ailawadhi of the Mayo Clinic at a poster session during the
52nd ASCO Annual Meeting in Chicago, Ill, discussed disparities observed
in treatment initiation between the two studied populations and the
impact of these disparities on patient outcomes.
"African Americans may be more at risk for developing multiple myeloma
than Caucasians, however, they often can have a better prognosis when
they get the proper care," said Dr. Manali Patel of the Stanford Cancer
Center and an investigator in the study. "Through studies like this, we
are trying to better understand potential modifiable drivers of these
disparities to improve outcomes for African Americans living with
The study found that elderly African Americans with multiple myeloma had
lower rates of receiving access to autologous stem cell transplant (3%
vs 6%, p < 0.01) and novel combination therapies (66% vs 74% among
patients with pharmacological therapy, p < 0.01) compared to Caucasians
with the disease. The median times from diagnosis to therapy initiation
(2.3 vs 1.7 months, p < 0.05) and novel therapy initiation (5.3 vs 3.1
months, p < 0.05) were also significantly longer for African Americans
than Caucasians. The study found, however, that overall survival (OS)
was comparable between African Americans and Caucasians (26.7 vs 30.0
months, p = 0.27) and total healthcare costs were similar across
cohorts, although African Americans had higher costs for
hospitalizations, emergency visits, and skilled nursing facility.
The study evaluated 2,200 Caucasian and 536 African American multiple
myeloma patients in the Surveillance, Epidemiology, and End Results
Program (SEER) Medicare database from 2007 and 2011, with the index date
being defined as the first date of diagnosis with multiple myeloma.
Patients were required to be continuously enrolled in Medicare Part A,
B, and D for six months before (baseline period) and at least six months
after the index date (study period), unless they died.
"Treatment disparities exist between African American and Caucasian
patients suffering from multiple myeloma," said Dr. Mohamad Hussein,
Vice President of Global Medical Affairs for Celgene. "At Celgene, we
believe it is imperative to improve education, awareness and treatment
access among African Americans, particularly since they are more
predisposed to being diagnosed with the disease."
Researchers determined that differences in disease aggressiveness and
other clinical characteristics at baseline between African Americans and
Caucasians should be explored in future studies as they can impact
Multiple myeloma is the second most common form of blood cancer in the
United States, and the most common blood cancer among African Americans.
African Americans are twice as likely to be diagnosed with multiple
myeloma. Novel therapeutic advances made in multiple myeloma over the
past decade have significantly improved outcomes for patients when they
receive access to timely care and treatment.
To address this disparity in multiple myeloma, Celgene created the "Standing
in the Gaap for African Americans with Multiple Myeloma" program in
2015 to raise awareness about how multiple myeloma affects African
Americans differently and to improve the quality of care they receive.
In addition to addressing treatment disparities and access for African
Americans with multiple myeloma, the program is committed to
understanding the genetic differences between African American patients
and other patients to better guide current treatment decisions and
future research. In addition, the program aims to improve enrollment of
African American multiple myeloma patients in clinical trials, which is
critical to accelerating knowledge gathering and new discoveries for
this highly fatal disease.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through
next-generation solutions in protein homeostasis, immuno-oncology,
epigenetics, immunology and neuro-inflammation. For more information,
please visit www.celgene.com.
Follow Celgene on Social Media: @Celgene,
This press release may contain forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and other reports filed with the Securities and Exchange
View source version on businesswire.com: http://www.businesswire.com/news/home/20160607006687/en/
Source: Celgene Corporation
News Provided by Acquire Media